Nanoparticles for cardiovascular diseases: identifying and overcoming barriers in translating preclinical success to clinical applications
Advanced Drug Delivery Reviews · 2026-12 · 239 · 115980
DOI: 10.1016/j.addr.2026.115980 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2026-12. Verfasst von Ali Ahmadi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Cardiometabolic mRNA Therapy, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia; Atherothrombosis and Vascular Biology La…. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Nanoparticles. Die Arbeit nennt 330 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Heart Foundation of Australia, NHMRC, The University of Melbourne.
Abstract (Originalsprache)
Nanoparticles (NPs) have emerged as versatile platforms for drug delivery in cardiovascular diseases (CVDs), demonstrating robust efficacy in preclinical models by stabilizing atherosclerotic plaques, promoting safe and efficient thrombolysis, and mitigating ischemia-reperfusion injury. These advances highlight the maturation of cardiovascular nanomedicine; however, translation to clinical practice remains limited. This gap between laboratory success and clinical adoption reflects broader challenges in nanomedicine design, including suboptimal delivery to diseased tissues, limited efficacy of single therapeutic payload-based strategies in addressing the multifaceted inflammatory pathways driving CVDs, NPs' immunogenicity, and scale-up feasibility. Addressing these barriers is particularly critical in CVDs, where therapeutic success depends on precise engagement with multiple molecular and cellular drivers of disease. This review discusses the evolving landscape of cardiovascular nanomedicine, focusing on four aspects. First, we highlight advances in NPs bioengineering strategies, such as refined targeting moieties, optimized physicochemical properties, and responsiveness to endogenous and external stimuli that enhance organ- and cell-specific delivery in atherosclerosis, myocardial infarction, and stroke. Second, we discuss analytical innovations that improve characterization and control of NPs' biodistribution, enabling more rational targeting. Third, we evaluate therapeutic payloads, emphasizing how RNA-based and immunomodulatory agents represent a meaningful step toward clinical translation. Fourth, we outline approaches to addressing persistent challenges in safety and scalable manufacturing. Together, these developments establish a foundation for translating NP design principles into practical cardiovascular therapies. With continued progress in targeted delivery, clinical safety, and production scalability, cardiovascular nanomedicine is increasingly well-positioned to translate preclinical advances to transformative patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centre for Cardiometabolic mRNA Therapy, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia; Atherothrombosis and Vascular Biology Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Aus…
- Centre for Cardiometabolic mRNA Therapy, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia; Molecular Imaging and Nanotherapeutics Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Au…
- Atherothrombosis and Vascular Biology Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia; Department of Cardiometabolic Health, University of Melbourne, Melbourne, VIC 3010, Australia; Austra…
Förderung
- National Heart Foundation of Australia
- NHMRC
- The University of Melbourne
Zitieren
APA
Ahmadi, A., Refaat, A., Miao, K., Vidallon, M. L. P., McFadyen, J. D., Wang, X., & Peter, K. (2026). Nanoparticles for cardiovascular diseases: identifying and overcoming barriers in translating preclinical success to clinical applications. Advanced Drug Delivery Reviews, 239, 115980. https://doi.org/10.1016/j.addr.2026.115980
Vancouver
Ahmadi A, Refaat A, Miao K, Vidallon MLP, McFadyen JD, Wang X, et al. Nanoparticles for cardiovascular diseases: identifying and overcoming barriers in translating preclinical success to clinical applications. Advanced Drug Delivery Reviews. 2026;239:115980. doi:10.1016/j.addr.2026.115980
BibTeX
@article{Ahmadi2026,
author = {Ahmadi, Ali and Refaat, Ahmed and Miao, Kaiting and Vidallon, Mark Louis P and McFadyen, James D and Wang, Xiaowei and Peter, Karlheinz},
title = {Nanoparticles for cardiovascular diseases: identifying and overcoming barriers in translating preclinical success to clinical applications},
journal = {Advanced Drug Delivery Reviews},
year = {2026},
volume = {239},
pages = {115980},
doi = {10.1016/j.addr.2026.115980}
}
EUVIMED